Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

Slides:

Advertisements

Similar presentations

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,

Advertisements

T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,

A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Joshua E. Rosen, BASc, Michelle C

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance.

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

The Impact of Symptoms, Coping Capacity, and Social Support on Quality of Life Experience Over Time in Patients with Lung Cancer Ingela Henoch, RN, PhD,

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Clinical Relevance of Our Multimodality Prognostic Score

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Stereotactic Body Radiotherapy for Central Lung Tumors

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial) Sonja Adebahr, MD, Marlene Hechtner, Nele Schräder, Tanja Schimek-Jasch, MD, Klaus Kaier, PhD, Viola Duncker-Rohr, MD, Eleni Gkika, MD, Felix Momm, MD, Jan Gaertner, MD, Gerhild Becker, MD, Anca-Ligia Grosu, MD, Ursula Nestle, MD Journal of Thoracic Oncology Volume 14, Issue 3, Pages 408-419 (March 2019) DOI: 10.1016/j.jtho.2018.10.170 Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Quality of life (QoL) changes from before fractionated stereotactic body radiotherapy (SBRT) to 7 weeks after SBRT assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 (A, B) and the QLQ LC13 lung cancer-specific questionnaire (C) regarding n = 97 patients of the prospective STRIPE cohort of pulmonary SBRT patients who filled out at least one questionnaire. Change (Δ) of group mean post-SBRT and pre-SBRT values are presented, MID (grey bar) represents the minimal important difference of 10 points. Neither QoL/global health status (GHS), nor function scores, nor symptom scales revealed any clinically relevant changes during short-time follow-up after SBRT of pulmonary lesions. PF, physical function; RF, role function; EF, emotional function; CF, cognitive function; SF, social function; LoA, loss of appetite; FD, financial difficulties; PN, peripheral neuropathy; MID, minimally important differences. Journal of Thoracic Oncology 2019 14, 408-419DOI: (10.1016/j.jtho.2018.10.170) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Subgroup analyses for patients with pulmonary malignancies treated with fractionated stereotactic body radiotherapy (SBRT). Change (Δ) of individualized mean values, 7 weeks post-SBRT – pre-SBRT values for the five predefined quality of life (QoL) scales of interest (QoL/ global health status [GHS], emotional function [EF], physical function [PF], fatigue, and dyspnea) are presented for subgroups of predefined patient- and treatment-related factors: (A) baseline QoL/GHS; (B) Karnofsky Index (KI); (C) age; (D) sex; (E) diagnosis; (F) tumor localization; (G) patient-rated dyspnea assessed by the lung cancer specific module (LC13) of the European Organization for Research and Treatment of Cancer QoL Questionnaire; (H) physician-rated dyspnea; (I) Charlson comorbidity index (CCI); (J) size of planning target volume (PTV); and (K) applied dose. Minimally important difference (grey bar) represents a difference of 10 points. BED, biological effective dose. Journal of Thoracic Oncology 2019 14, 408-419DOI: (10.1016/j.jtho.2018.10.170) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Subgroup analyses for patients with pulmonary malignancies treated with fractionated stereotactic body radiotherapy (SBRT). Change (Δ) of individualized mean values, 7 weeks post-SBRT – pre-SBRT values for the five predefined quality of life (QoL) scales of interest (QoL/ global health status [GHS], emotional function [EF], physical function [PF], fatigue, and dyspnea) are presented for subgroups of predefined patient- and treatment-related factors: (A) baseline QoL/GHS; (B) Karnofsky Index (KI); (C) age; (D) sex; (E) diagnosis; (F) tumor localization; (G) patient-rated dyspnea assessed by the lung cancer specific module (LC13) of the European Organization for Research and Treatment of Cancer QoL Questionnaire; (H) physician-rated dyspnea; (I) Charlson comorbidity index (CCI); (J) size of planning target volume (PTV); and (K) applied dose. Minimally important difference (grey bar) represents a difference of 10 points. BED, biological effective dose. Journal of Thoracic Oncology 2019 14, 408-419DOI: (10.1016/j.jtho.2018.10.170) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions